This page summarizes published research used as background for consultation. It does not show treatment effects at our clinic, promise outcomes, or replace an individual medical assessment.
As we age, our bodies accumulate senescent cells — sometimes called "zombie cells." These cells no longer divide or function normally, but they refuse to die. Instead, they secrete a cocktail of inflammatory signals known as the SASP (Senescence-Associated Secretory Phenotype), which includes IL-6, TNF-α, and CRP.
This chronic, low-grade inflammation is now recognized as a root driver of aging and age-related diseases including cardiovascular disease, neurodegeneration, diabetes, and cancer.
Natural Killer (NK) cells are your body's built-in senolytic system. They recognize and eliminate senescent cells through specific receptors (NKG2D, DNAM-1, NKp46). However, NK cell function declines significantly with age — precisely when senescent cell burden increases.
Research on NK cells, immune surveillance, and cellular senescence can help frame a medical consultation. It does not determine whether any specific procedure is appropriate for an individual.
From foundational Nature discoveries to randomized controlled trials in humans.
Nakazawa T, Matsuda R, et al. — Grandsoul Research Institute / Nara Medical University / UC San Diego
This review summarizes research on NK cells, immune surveillance, and cellular senescence. It is useful background for physician discussion, not a ranking or a patient-specific recommendation.
Why this matters for patients: This review is useful background when discussing immune surveillance, cellular senescence, and inflammation with a physician. It should not be read as proof of a specific clinical outcome or as a promise that one approach addresses multiple age-related conditions.
Tang X, et al.
A prospective, open-label, randomized controlled trial — the gold standard of clinical evidence. 25 elderly patients were randomized to receive autologous NK cell infusions or no treatment, with results measured at 90-day follow-up.
Why this matters for patients: This controlled clinical study provides research context for discussing immune markers and inflammatory signals. It should not be read as proof that adverse events cannot occur, a promised outcome, or a substitute for individual medical judgment.
Sen Santara S, et al.
Published in Nature, this paper discusses a molecular pathway by which NK-cell receptors recognize markers associated with cellular stress and senescence. It should be read as mechanism research, not as a patient-outcome statement.
Why this matters for patients: Mechanism papers can help explain why immune markers may be discussed during consultation. They do not prove that a clinic procedure will produce a specific result.
Yousefzadeh MJ, et al.
A Nature paper examining how immune-cell aging relates to wider age-associated changes in experimental models. It is useful research background, but it should not be translated directly into a promised human clinical effect.
Why this matters for patients: This Nature paper helps explain why immune markers may be discussed during a broader review of aging, inflammation, and health status. Individual decisions still require medical consultation and cannot be inferred from this paper alone.
Bai J, et al.
A clinical study with 26 human volunteers receiving autologous NK cell infusions. This paper provides direct human evidence that NK cell therapy reduces measurable biomarkers of cellular senescence in both blood and tissue samples.
Chelyapov N, et al.
An in vitro study with 5 healthy volunteers examining cellular and inflammatory markers under study conditions. It provides research context for follow-up discussion, not a fixed protocol recommendation.
Why this matters for patients: This study helps frame why repeated measurement and physician review may be discussed. It does not validate a fixed protocol, promise a response, or establish safety for every individual.
Kang TW, et al.
Another Nature publication examining how NK-cell immune surveillance relates to senescent cells and cancer biology. This is research background for medical discussion, not a statement that a specific intervention prevents cancer.
Why this matters for patients: Cancer-related risk review should combine screening, imaging, laboratory findings, history, and physician judgment. This research supports discussion of immune surveillance as background, not a promise of reducing cancer risk.
| Paper | Journal | Type | Key Contribution |
|---|---|---|---|
| Nakazawa 2025 | Frontiers in Immunology | Comprehensive Review | Summarizes NK-cell surveillance and senescence research background |
| Tang 2022 | Frontiers in Immunology | Randomized Controlled Trial | 25 patients, 90-day data, adverse-event reporting in the study population |
| Sen Santara 2023 | Nature | Mechanism Discovery | NKp46 receptor identification for senescent cell recognition |
| Yousefzadeh 2021 | Nature | Foundational Research | Discusses immune aging and whole-body aging in research models |
| Bai 2022 | Cell Death & Disease | Human Clinical (n=26) | Measurable senescence marker reduction in humans |
| Chelyapov 2022 | Biochem Biophys Rep | Repeat Dosing | Repeated measurement and follow-up were discussed in the study context |
| Kang 2011 | Nature | Cancer Surveillance | NK cells prevent pre-cancerous cell progression |
This table separates research themes. It is not a treatment comparison, ranking, or recommendation.
| Factor | Cell-Based Consultation Context | Drug Senolytic Literature Context |
|---|---|---|
| Research Focus | Immune surveillance and senescent-cell markers are discussed as biological background. | Drug papers often discuss senescent-cell pathways and candidate compounds. |
| Safety Review | Safety is reviewed individually with records, consent, and physician explanation. | Safety profiles vary by compound, study design, dose, and patient population. |
| Follow-Up | Follow-up discussion may include symptoms, imaging, laboratory data, and inflammatory markers. | Study protocols and observation periods differ across publications. |
| Clinical Context | Cell condition, patient condition, records, and quality documents must be reviewed together. | Drug mechanisms should not be treated as proof of cell-based clinical effects. |
| Regulatory Status | Japanese regenerative-medicine procedures require proper notification, consent, and physician-led explanation. | Development status differs by compound and jurisdiction. |
| Cancer-Risk Review | Cancer-related risk review should combine screening, imaging, laboratory data, history, and physician judgment. | Mechanism papers are research background, not a substitute for cancer screening or specialist care. |
Speak with our concierge to organize your records and discuss which questions should be reviewed with a physician.